We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Exploring the Biopharma Industry's Evolving Risk Model

Exploring the Biopharma Industry's Evolving Risk Model

Exploring the Biopharma Industry's Evolving Risk Model

Exploring the Biopharma Industry's Evolving Risk Model

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exploring the Biopharma Industry's Evolving Risk Model "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Merck has announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape. The survey, sponsored by Merck, was conducted by the Economist Intelligence Unit (EIU), a leading resource for economic and business research, forecasting and analysis. Findings will be presented on June 8 at the 2016 BIO International Convention in San Francisco, California. 

"In response to the uncertainty and disruption facing the biopharmaceutical industry, Merck has moved beyond old risk-management models and has adopted and is applying new strategies at the earliest stages of development and seeing them through to commercialization," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.

Study highlights include:

48 percent of respondents are developing or will develop novel therapies, such as gene and cell therapies

Biopharmas anticipate entering South Korea, Indonesia and Taiwan in the next five years

Regulatory uncertainty tops the list of risks that biopharma executives think might disrupt their company's strategy in the next five years (32 percent)

80 percent of respondents are highly optimistic about their company's ability to bring new drug products to market over the next five years

Manufacturers in the biopharma industry face unprecedented challenges as they enter unfamiliar geographies, aggressively replenish pipelines and expand into novel areas such as gene and cell therapies requiring more complex development and production. The EIU study, detailed in The Changing Biopharma Risk Equation, examines how new growth strategies are creating exposure to different types of risk and explores options for successfully navigating this unexplored territory.

Survey respondents offered a global view with 31 percent from Europe, 30 percent from North America, 29 percent from Asia and 10 percent from the rest of the world. Responses also reflect the differences in view depending on company size, with 50 percent of participants coming from biopharmas with less than $500 million in revenues and 50 percent from larger players.